BACKGROUND: Responses to influenza vaccines are poorly characterized in immunocompromised patients. The goal of this study was to assess the efficacy of the AS03-adjuvanted influenza H1N1/A/09 vaccine in allogeneic hematopoietic stem cell transplant recipients. DESIGN AND METHODS: We enrolled 65 patients and 138 controls in an open prospective study. Controls received one dose and patients 2 doses of the AS03-adjuvanted influenza H1N1/A/09 vaccine at a 3-week interval. Geometric mean titers and seroprotection/seroconversion rates were determined by hemagglutination inhibition before and four weeks after the last immunization. Clinical and biological markers, including immunoglobulins, CD3+, CD4+, CD8+ and naïve CD4+ T-cell counts were assessed in all patients. RESULTS:Baseline seroprotection rates were low in patients (6.6%) and controls (14.8%). After 2 doses, patients (n=57, 92.3%) achieved similar seroprotection rates (84% vs. 87%, P=0.65) and antibody titers (305 vs. 340, P=0.88) as controls (n=131, 93.9%) after one dose. In univariate analysis, transplant-to-vaccination interval less than 12 months, active graft-versus-host disease, immunosuppressive drugs, hemoglobin less than 12 g/L, lymphopenia less than 1 G/L, IgG less than 4 g/L, IgA less than 0.5 g/L, IgM less than 0.5 g/L and naive CD4+ T cells less than 150/μL were significantly associated with weaker responses. Multivariate analysis identified transplant-to-vaccination interval and active graft-versus-host disease as the most powerful negative predictors of antibody responses (P=0.04 and P=0.002, respectively). Vaccination was well tolerated in both cohorts. CONCLUSIONS: In allogeneic hematopoietic stem cell transplant recipients, 2 doses of an adjuvanted influenza vaccine elicited comparable responses to a single dose in healthy individuals. However, vaccine responses remained poor in patients with ongoing graft-versus-host disease, supporting the need for additional strategies in this high-risk patient population. (ClinicalTrials.gov Identifier: NCT01022905).
RCT Entities:
BACKGROUND: Responses to influenza vaccines are poorly characterized in immunocompromised patients. The goal of this study was to assess the efficacy of the AS03-adjuvanted influenza H1N1/A/09 vaccine in allogeneic hematopoietic stem cell transplant recipients. DESIGN AND METHODS: We enrolled 65 patients and 138 controls in an open prospective study. Controls received one dose and patients 2 doses of the AS03-adjuvanted influenza H1N1/A/09 vaccine at a 3-week interval. Geometric mean titers and seroprotection/seroconversion rates were determined by hemagglutination inhibition before and four weeks after the last immunization. Clinical and biological markers, including immunoglobulins, CD3+, CD4+, CD8+ and naïve CD4+ T-cell counts were assessed in all patients. RESULTS: Baseline seroprotection rates were low in patients (6.6%) and controls (14.8%). After 2 doses, patients (n=57, 92.3%) achieved similar seroprotection rates (84% vs. 87%, P=0.65) and antibody titers (305 vs. 340, P=0.88) as controls (n=131, 93.9%) after one dose. In univariate analysis, transplant-to-vaccination interval less than 12 months, active graft-versus-host disease, immunosuppressive drugs, hemoglobin less than 12 g/L, lymphopenia less than 1 G/L, IgG less than 4 g/L, IgA less than 0.5 g/L, IgM less than 0.5 g/L and naive CD4+ T cells less than 150/μL were significantly associated with weaker responses. Multivariate analysis identified transplant-to-vaccination interval and active graft-versus-host disease as the most powerful negative predictors of antibody responses (P=0.04 and P=0.002, respectively). Vaccination was well tolerated in both cohorts. CONCLUSIONS: In allogeneic hematopoietic stem cell transplant recipients, 2 doses of an adjuvanted influenza vaccine elicited comparable responses to a single dose in healthy individuals. However, vaccine responses remained poor in patients with ongoing graft-versus-host disease, supporting the need for additional strategies in this high-risk patient population. (ClinicalTrials.gov Identifier: NCT01022905).
Authors: Beatrix Grubeck-Loebenstein; Silvia Della Bella; Anna Maria Iorio; Jean-Pierre Michel; Graham Pawelec; Rafael Solana Journal: Aging Clin Exp Res Date: 2009-06 Impact factor: 3.636
Authors: K Weinberg; B R Blazar; J E Wagner; E Agura; B J Hill; M Smogorzewska; R A Koup; M R Betts; R H Collins; D C Douek Journal: Blood Date: 2001-03-01 Impact factor: 22.113
Authors: N Khanna; I Steffen; J-D Studt; A Schreiber; T Lehmann; M Weisser; U Flückiger; A Gratwohl; J Halter; H H Hirsch Journal: Transpl Infect Dis Date: 2009-01-20 Impact factor: 2.228
Authors: Anne Reilly; Leslie S Kersun; Eline Luning Prak; Jean Boyer; Kenyetta McDonald; Abbas F Jawad; Kathleen E Sullivan Journal: J Pediatr Hematol Oncol Date: 2013-01 Impact factor: 1.289
Authors: Andreas F Hottinger; Anne-Claude C George; Michael Bel; Laurence Favet; Christophe Combescure; Sara Meier; Stéphane Grillet; Klara Posfay-Barbe; Laurent Kaiser; Claire-Anne Siegrist; Pierre-Yves Dietrich Journal: Oncologist Date: 2012-02-21
Authors: Nicole A Karras; Matthew Weeres; Wendy Sessions; Xiyan Xu; Todd Defor; Jo-Anne H Young; Heather Stefanski; Claudio Brunstein; Sarah Cooley; Jeffrey S Miller; Bruce R Blazar; John E Wagner; Michael R Verneris Journal: Biol Blood Marrow Transplant Date: 2012-08-29 Impact factor: 5.742
Authors: Sebastian Kobold; Tim Luetkens; Britta Marlen Bartels; Yanran Cao; York Hildebrandt; Orhan Sezer; Henrike Reinhard; Julia Templin; Katrin Bartels; Nesrine Lajmi; Friedrich Haag; Carsten Bokemeyer; Nicolaus Kröger; Djordje Atanackovic Journal: Clin Dev Immunol Date: 2012-03-12